. 参考文献: Nikolic Nikola , et al., Brief Report: Predictive value of PD-L1 expression in non-small-cell lung can- cer - should we set the bar higher for monotherapy?, Clinical Lung Cancer (2023) 发布于 2023-05-15 21:08・北京 ...
近日,Clinical Lung Cancer发表了一篇非常有趣的治疗个案。患者在PD1耐药后尝试PDL1竟然取得了很好的效果。这种治疗方案并非凭空而来,其实还有一定的细节讲究,一起来看看。 病·例·分·享 基本情况:局晚期TP53突变、PDL1阳性老年患者 患者,女,79岁,吸烟者,...
1. Lucio Crinò et al. Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer.2019 2. Shirish M. Gadgeel et al. Atezolizumab in patients with advanced non-small cell lung cancer and history of asymp...
PD-L1 gene expression in Japa- nese lung cancer patients. Biomed Rep. 2013;1(1):93-96.Sasaki H, Suzuki A, Shitara M, et al. PDL1 gene expres- sion in Japanese lung cancer patients. Biomed Rep 2013;1: 93--6.Sasaki H, Suzuki A, Shitara M, et al. PD-L1 gene expression in ...
[1]Felip E, Altorki N, Zhou C, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2021 Sep 17:S0140-6736(21)02098-5. doi: 10.1016/S0140-6736(21)020...
靶向治疗是驱动基因阳性的NSCLC患者的首选治疗方案,免疫治疗是驱动基因阴性NSCLC患者的首选治疗方案,两种疗法一直分庭抗礼,对于驱动基因阳性的NSCLC患者,临床上一般不推荐免疫治疗。但是靶向药物不可避免的出现耐药情况,EGFR突变患者使用三代EGFR-TKI奥希替尼耐药后无药可用,免疫治疗能否有效呢?Lung Cancer上的一篇文章中提...
4.ElizabethDudniketal.IntracranialresponsetonivolumabinNSCLCpatientswithuntreatedorprogressingCNSmetastases.2016 5.SarahBGoldbergetal.Pembrolizumabforpatientswithmelanomaornon-small-celllungcanceranduntreatedbrainmetastases:earlyanalysisofanon-randomised,open-label,phase2trial.2016 ...
5. Reck M, CIuleanu TE, Cobo M, et al. First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): Two-year update from CheckMate 9LA. J Clin Oncol. 2021;39...
3.I-SPY2 Trial Consortium, Yee D, DeMichele AM, et al. Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized...
Takano A, Ong BH, Tan EH, Tan SH, Skanderup AJ, Tan DSW. PD-L1 score as a prognostic biomarker in asian early-stage epidermal growth factor receptor-mutated lung cancer. Eur J Cancer. 2022 Oct 20;178:139-149. doi: 10.1016/j.ejca.2022.10.012. Epub ahead of print. PMID: 36436331...